

us-10-026-106e-7.rng

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

```
Run on: September 17, 2003, 16:20:15 ; Search time 310.324 Seconds
        (without alignments)
        13909.353 Million cell updates/sec
```

Sequence: 1 aagggccatggcgggcccgaa.....acatcccaacggaatctgatg 1599

Searched: 2552756 seqs, 1349719017 residues

Maximum DB seq length: 20000000000

Listing first 45 summaries

Database : N_Geneseq_19Jun03:*

1	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1980.DAT.*
2	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1981.DAT.*
3	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1982.DAT.*
4	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1983.DAT.*
5	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1984.DAT.*
6	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1985.DAT.*
7	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1986.DAT.*
8	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1987.DAT.*
9	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1988.DAT.*
10	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1989.DAT.*
11	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1990.DAT.*
12	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1991.DAT.*
13	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1992.DAT.*
14	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1993.DAT.*
15	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1994.DAT.*
16	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1995.DAT.*
17	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1996.DAT.*
18	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1997.DAT.*
19	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1998.DAT.*
20	/SID1/gcgdata/genseeq/genseeqn-emb1/NA1999.DAT.*
21	/SID1/gcgdata/genseeq/genseeqn-emb1/NA2000.DAT.*
22	/SID1/gcgdata/genseeq/genseeqn-emb1/NA2001A.DAT.*
23	/SID1/gcgdata/genseeq/genseeqn-emb1/NA2001B.DAT.*
24	/SID1/gcgdata/genseeq/genseeqn-emb1/NA2002.DAT.*
25	/SID1/gcgdata/genseeq/genseeqn-emb1/NA2003.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	length	DB	ID	Description
1	1549.4	96.9	1563	24	AB073078	Human zcytor19 enc
2	1549.4	96.9	1563	25	AB050487	Human zcytor19 enc
3	1354.2	84.7	1476	24	AB073068	Human zcytor19 enc
4	1354.2	84.7	1476	25	AB050485	Human zcytor19 enc
5	1086.8	68.0	1560	24	AB073085	Human zcytor19 desig
6	916.2	57.3	1473	24	AB073069	Human zcytor19 desig
7	609.4	38.1	1922	24	AB073089	MBP and zcytor19 f
8	607.4	38.0	1422	24	AB073080	Zcytor19 and Fcγ4 f

9	498	31.1	673	24	AADQ7307
10	498	31.1	674	25	AAD50489
11	498	31.1	704	24	AAD35322
12	351.2	22.0	63	24	AAD37086
13	335.4	21.0	374	22	AAFB4466
14	165	10.3	392	22	AAFB5622
15	163.4	10.2	382	22	AAFB6532
16	128	8.0	634	22	AAH35777
17	53.4	3.3	337	22	AAH35707
18	48.8	3.1	470	22	AAH66622
19	44.4	2.8	148	22	AAH86622
20	44.4	2.8	3112	24	ABSF7522
21	44.4	2.8	3115	22	ABH08677
22	44.4	2.8	3115	22	AAH99566
23	44.4	2.8	3142	20	AAFB2809
24	44.4	2.8	3147	20	AAH87811
25	44.4	2.8	3147	22	AAD11111
26	44.4	2.8	3147	22	AAH11111
27	44.4	2.8	3147	22	AAH26070
28	44.4	2.8	3147	22	AAH26030
29	44.4	2.8	3147	24	AAH35444
30	44.4	2.8	3147	24	AAH54544
31	44.4	2.8	3147	25	ABZ58500
32	44.4	2.8	3147	25	ABZ58500
33	44.4	2.8	3147	25	ABZ22455
34	44.4	2.8	3147	25	ABZ22455
35	44.4	2.8	3147	25	ABD22455
36	44.4	2.8	3147	25	ABD41180
37	44.4	2.8	3147	25	ABD41180
38	44.4	2.8	3147	25	AAH44422
39	44.4	2.8	3147	21	AAH84422
40	44.4	2.8	3152	21	AAH57431
41	44.4	2.8	3159	21	AAH31655
42	44.4	2.8	3413	21	AAH85662
43	44.2	2.6	971	21	AAH85662
44	44.2	2.6	3780	22	AAH31823
45	44.2	2.6	4174	22	AAH31823
	42	2.6	2900	22	AAH326020

ALIGNMENTS

Human	cytochrome c
Human	zcytor9
Human	(DNX) inter
Human	zcytor19
Novel	human poly
Novel	human poly
Human	colon cancer
Human	immune/hem
Human	immune/hem
DNA encoding	novel
cDNA encoding	human
Human	membrane-ty
Human	protein enc
Human	membrane-ty
Tumour	antigen det
Human	membrane-ty
Human	membrane-ty
Human	TADG-15 cod
Human	TADG-15 ant
Type II	transmembr
Type II	transmembr
Transmembrane	seri
Human	membrane-ty
Human	MTSP1 prote
Human	membrane-ty
Human	membrane-ty
Human	matricellase
Human	interleukin
Human	peptidase, H
DNA encoding	novel
Human	tumour supp
DNA encoding	human
Human	SNC-19 codin

	FT	mat_peptide	61..1560	
	PT	/+cage= C /product= "mature zcytor19"		
	XX			
	PX	MQ2002A420S-A2.		
	PN			
	PD	06-JUN-2002.		
	PP	28-NOV-2001; 2001MO-US#44808.		
	PR	28-NOV-2000; 2000US-253561P.		
	PS	07-FEB-2001; 2001US-267211P.		
	PA	(ZYWO) ZYMOGENETICS INC.		
	PI	Fresnell SR, Xu W, Novak JE, Whitmore TE, Grant FU,		
	DJ	WFI, 2002-527700/56.		
	DR	p-PDB; ABBB1643.		
	CC	The present invention describes an isolated human zcytor19 protein (I),		
	CC	and truncated zcytor19 proteins. (I) has immunosuppressive, cytostatic,		
	CC	antirheumatic, antiarthritic, neuroprotective, antiinflammatory,		
	CC	antiidiabetic, nephrotoxic, dermatological, anti-HIV and haemostatic		
	CC	activities, and can be used in vaccines. (I) or an antibody binding (I)		
	CC	can be used for suppressing the immune system for reducing rejection of		
	CC	tissue or organ transplants and grafts and for treating T-cell specific		
	CC	leukemias or lymphomas and autoimmune diseases including rheumatoid		
	CC	arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel		
	CC	disease and Crohn's disease. The antibodies can also be used for treating		
	CC	immunologic renal diseases, glomerulonephritis, mesangiolproliferative		
	CC	diseases, chronic lymphocytic leukemia, secondary glomerulonephritis or		
	CC	vasculitis associated with lupus, polyarteritis, scleroderma, HIV-related		
	CC	diseases, amyloidosis and haemolytic uremic syndrome. (I) and the		
	CC	antibodies can also be used for renal or urological neoplasms and		
	CC	multiple myeloma, asthma, bronchitis, emphysema and other chronic		
	CC	airway diseases. Human zcytor19 is located to chromosome 1, more		
	CC	specifically to chromosome 1p31.1. The present sequence encodes a human		
	CC	zcytor19 protein from the present invention.		
	XX			
SQ	Sequence 1563 BP; 335 A; 468 C; 471 G; 289 T; 0 Other;			
	Query Match	96.9%; Score 1549.4; DB 24; Length 1563;		
	Best Local Similarity	99.9%; Pred. No. 0;		
	Matches 1561; Conservative	0; Mismatches 1; Indels 1; Gaps 1		
OY	7 ATGGGCGAGGCCCAAGCCTGTGGCCCCCTGCCTTCCTTGCCTGTACAGCGCTCACAGG	66		
Db	1 ATGGGCGAGGCCCAAGCCTGTGGCCCCCTGCCTTCCTTGCCTGTGAAGCGCTCACAGG	60		
OY	67 AGGCCCGGTCTGAGCCCCTCCCAAATGTAGCGTGCTCCCAAATTAGAAGGTACT	126		
Db	61 AGGCCCGGTCTGAGCCCCTCCCAAATGTAGCGTGCTCCCAAATTAGAAGGTACT	120		
OY	127 CTGACATGCGCTCCAGAGGCTTTGGCAACCCTTAGCATTAATTGTGGCC-ATCAG	185		
Db	121 CTGACATGCGCTCCAGAGGCTTTGGCAACCCTTAGCATTAATTGTGGCTTACA	180		
OY	186 ACCTTCACCAACCGTAGAGCGGTGCGCAATGTAAAGTGTGCGGAACCAAGAAC	245		
Db	181 ACCTTCACCAACCGTAGAGCGGTGCGCAATGTAAAGTGTGCGGAACCAAGAAC	240		
OY	246 CATATTCATATGATGAGCTGTAAATAAGACCTGTATCAACAAGTCAAGGACGGGT	305		
Db	241 CATATTCATATGATGAGCTGTAAATAAGACCTGTATCAACAAGTCAAGGACGGGT	300		
OY	306 CGAGCGTTTTCTCCCAAGCTCAAGTCCCTCTGGGTGAGTCGAATACCTGGATTACTT	365		

D	301	CGAGCGTTTCTTCCAGCTCCAAATCCCCCTGGGTGAGTCCGAATACCTGATTACCTT	360
Q	366	TTTGAGTGGAGCCGGCCCCACCTGTCTCTGTGTCTACCCAGACGGAGAGATCCTGACT	425
D	361	TTTGAATGGAGCCGGCCCCACCTGTCTCTGTGTCTACCCAGAGCGAGAGATCCTGACT	420
Q	426	GCCAAATGCCACGTACCAAGTCCCCCTGTGATGCCCCACCTGGAATCTGAAGTATGAGGTG	485
D	421	GCCAAATGCCACGTACCAAGTCCCCCTGTGATGCCCCACCTGGAATCTGAAGTATGAGGTG	480
Q	486	GCATTCTGGAGAGAGAGGGGGCCGGAAAACAAGACCTATTTCAGATCACTCCCAATGCCAG	545
D	481	GCATTCTGGAGAGAGAGGGGGCCGGAAAACAAGACCTATTTCAGATCACTCCCAATGCCAG	540
Q	546	CCAGTCCAGATCACTTCTCAGCCAGCTGGCCAGGAACAACATCCTCAATGTCAGAACCC	605
D	541	CCAGTCCAGATCACTTCTCAGCCAGCTGGCCAGGAACAACATCCTCAATGTCAGAACCC	600
Q	606	ATTACACAGTTCAGTGTGTCGCCGAAATACAGCAAGTTCTCTAAGCCCACTGCTCTTGCTG	665
D	601	ATTACACAGTTCAGTGTGTCGCCGAAATACAGCAAGTTCTCTAAGCCCACTGCTCTTGCTG	660
Q	666	GAGTCCCAGAAAGCCAACTGGGGCTTTTCTGTGTCTGCCATCGCTTCTGATACGTGCTTGA	725
D	661	GAGTCCCAGAAAGCCAACTGGGGCTTTTCTGTGTCTGCCATCGCTTCTGATACGTGCTTGA	720
Q	726	GTAATTGCCGAGGGGGTGTGATCTGGAGAGACCTCATGGGGAAACCCCTGTTTCAACCG	785
D	721	GTAATTGCCGAGGGGGTGTGATCTGGAGAGACCTCATGGGGAAACCCCTGTTTCAACCG	780
Q	786	GCAAGATGCCAGGGGGCTTGGACTTTTCTGGACACACACACCTGTGGGAACTTTTCAAG	845
D	781	GCAAGATGCCAGGGGGCTTGGACTTTTCTGGACACACACACCTGTGGGAACTTTTCAAG	840
Q	846	CCCAAGCAGACCAAGATCCGTGATGATGACTTGTCTCTGTCTCCCAAAAGAACTGACACA	905
D	841	CCCAAGCAGACCAAGATCCGTGATGATGACTTGTCTCTGTCTCCCAAAAGAACTGACACA	900
Q	906	GGGGTCAAGGCCAGCCTCTGAGTCAGAGGCCCCAGCCACCCAAACAGACAGATGGAAGAG	965
D	901	GGGGTCAAGGCCAGCCTCTGAGTCAGAGGCCCCAGCCACCCAAACAGACAGATGGAAGAG	960
Q	966	GACCTTGCAGAGAGAGAGAGAGAGAGATGAGAGAGACAAGAAATGAGGCTCAAGCTTC	1025
D	961	GACCTTGCAGAGAGAGAGAGAGAGAGATGAGAGAGACAAGAAATGAGGCTCAAGCTTC	1020
Q	1026	CAGCCCTAACATTGAACCACTTTCTTTCTGTGGGCAAGACCAAGGCTCAAGGGCACTGG	1085
D	1021	CAGCCCTAACATTGAACCACTTTCTTTCTGTGGGCAAGACCAAGGCTCAAGGGCACTGG	1080
Q	1086	GAGGCTGTGGGTGAGACTCAAGGAGGGCCCAAGGCTCTCTGTGTCCCAACGAAAGCTCC	1145
D	1081	GAGGCTGTGGGTGAGACTCAAGGAGGGCCCAAGGCTCTCTGTGTCCCAACGAAAGCTCC	1140
Q	1146	TTGTGCTTGGGATTTTTCAGACAGAAAGTGGGCCACATCTGTGACTCTTCTGTGGACAAG	1205
D	1141	TTGTGCTTGGGATTTTTCAGACAGAAAGTGGGCCACATCTGTGACTCTTCTGTGGACAAG	1200
Q	1206	GCTGGGTCTCTTGACTTATTTGGCTGAGAAAGGGCCAGGCAAGGGCCGGGTGGGATGAG	1265
D	1201	GCTGGGTCTCTTGACTTATTTGGCTGAGAAAGGGGCCAGGCAAGGGCCGGGTGGGATGAG	1260
Q	1266	CACCAAGAAATCTCTCCCAACCACTGAATTCCTCCAGAGACTGGGGTTTCTGGAAAGCTCC	1325
D	1261	CACCAAGAAATCTCTCCCAACCACTGAATTCCTCCAGAGACTGGGGTTTCTGGAAAGCTCC	1320
Q	1326	CCAGAGATTAACCTCTCTCTGTGGGCCACTGTGGGCACTTAAACAACGGAGCCGAATCTG	1385
D	1321	CCAGAGATTAACCTCTCTCTGTGGGCCACTGTGGGCACTTAAACAACGGAGCCGAATCTG	1380
Q	1386	GTCCCTGGGGAGACCCCAAGTTTCTTTCAACAATGAACCTTCTGTCTGGGAAACACCTCT	1445

Qy	906	GGGGGTCAAGGCGCCACGCGCTCGAGTCAAGGGGCCCCCAAGCCACCAACGACGACATGTAAGAAAG	965
Db	901	GGGGTCAAGGCGCCACGCGCTCGAGTCAAGGGGCCCCCAAGCCACCAACGACGACATGTAAGAAAG	960
Qy	966	GACCTTGCAGAGGACCGAAGAGAGAGAGATGAGAGAGACACAGAAATGCGCTCAGCTTC	1025
Db	961	GACCTTGCAGAGGACCGAAGAGAGAGAGATGAGAGAGACACAGAAATGCGCTCAGCTTC	1020
Qy	1026	CAGCGCTCAGCTTGAACCAACCTCTCTTCTCTGGGGCAGAGCAACAGGCTCCAGGGCAGCTCG	1085
Db	1021	CAGCGCTCAGCTTGAACCAACCTCTCTTCTCTGGGGCAGAGCAACAGGCTCCAGGGCAGCTCG	1080
Qy	1086	GAGGCTGTGTGGGTGGACCTCAGAGGAGGCCACAGGGGCTCTGTGTGCCAAGAGGCTCC	1145
Db	1081	GAGGCTGTGTGGGTGGACCTCAGAGGAGGCCACAGGGGCTCTGTGTGCCAAGAGGCTCC	1140
Qy	1146	TCTGCTTGGGATTCCTTCAGACAGAAAGCTGGGCGACACTGTGAACTCCTCTGGGACAGG	1205
Db	1141	TCTGCTTGGGATTCCTTCAGACAGAAAGCTGGGCGACACTGTGAACTCCTCTGGGACAGG	1200
Qy	1206	GCTGGGCTCTCTGGCTATTGTGCTGAGAAAGGGGCGAGGGCCAGAGGCTGGGGATGAGG	1265
Db	1201	GCTGGGCTCTCTGGCTATTGTGCTGAGAAAGGGGCGAGGGCCAGAGGCTGGGGATGAGG	1260
Qy	1266	CACCAAGAAATCTCTCCCAACACTGGAATATCTCCAGAGAACTCGGGTTCTGTGAAGAGCTC	1325
Db	1261	CACCAAGAAATCTCTCCCAACACTGGAATATCTCCAGAGAACTCGGGTTCTGTGAAGAGCTC	1320
Qy	1326	CCAGAAAGATAACCTCTCTCTCTGTGGGCCACCTGTGGGCGACCTTACCAACCGAGACCGAATCTG	1385
Db	1321	CCAGAAAGATAACCTCTCTCTCTGTGGGCCACCTGTGGGCGACCTTACCAACCGAGACCGAATCTG	1380
Qy	1386	GTCCCTGTGGGGGACCCGCCAATTTCTTTTACAGCACTGACACTGTGTGTGGGAAACAGACCTT	1445
Db	1381	GTCCCTGTGGGGGACCCGCCAATTTCTTTTACAGCACTGACACTGTGTGTGGGAAACAGACCTT	1440
Qy	1446	GAGGAGGAAAGAGAGGCGCAGGGAAATCAGAAATTGAGGACAGCGATGCGGGGACGTGGGGG	1505
Db	1441	GAGGAGGAAAGAGAGGCGCAGGGAAATCAGAAATTGAGGACAGCGATGCGGGGACGTGGGGG	1500
Qy	1506	GCTGAGAGACACCCAGAGAGACCGAGGACAGGGGGCCGACATTGGGGCATTATATGGCCAGG	1565
Db	1501	GCTGAGAGACACCCAGAGAGACCGAGGACAGGGGGCCGACATTGGGGCATTATATGGCCAGG	1560
Qy	1566	TGA 1566	
Db	1561	TGA 1563	
RESULT 3			
ABQ73068			
ID	ABQ73068	standard, cDNA, 1476 BP.	
XX	AC	ABQ73068;	
XX	AC		
DT	25-SEP-2002	(first entry)	
XX	DE	Human zcytor19 encoding cDNA SEQ ID NO:1.	
XX	XX	Human, zcytor19; cytokine receptor; immunosuppressive; cytostatic;	
KW	KM	antitubercular; antitubercular; neuroprotective; anti-inflammatory;	
KW	KM	antidiabetic; nephrotropic; dermatological; anti-HIV; haemostatic;	
KW	KM	vaccine; immune system; T-cell specific leukaemia; lymphoma; lupus;	
KW	KM	autoimmune disease; rheumatoid arthritis; multiple sclerosis; HIV;	
KW	KM	diabetes mellitus; inflammatory bowel disease; Crohn's disease; asthma;	
KW	KM	neurologic renal disease; glomerulonephritis; vasculitis; polyarteritis;	
KW	KM	neuroproliferative disease; chronic lymphocytic leukaemia; bronchitis;	
KW	KM	secondary glomerulonephritis; scleroderma; amyloidosis; multiple myeloma;	
KW	KM	haemolytic uraemic syndrome; renal neoplasia; urological neoplasm;	
KW	KM	emphysema; chronic airway disease; chromosome 1; chromosome 1p36.11;	
OS	gene; ss.		
OS	Homo sapiens.		

XX	key		Location/Qualifiers
FH	CDS	1..1473	/...tag= a
FT		/product= "zcytor19"	
FT	sig_peptide	1..60	/...tag= b
FT	mat_peptide	61..1470	/...tag= c
FT		/product= "mature zcytor19"	
FN			
PV			
PD			
PE	-06-JUN-2002.		
PP	28-NOV-2001; 2001MO-US44808.		
PR	28-NOV-2000; 2000US-253561P.		
PR	07-FEB-2001; 2001US-267211P.		
PA	(ZYMO) ZYMOGENETICS INC.,		
PI	Presnell SR, Xu W, Novak JE, Whitmore TE, Grant FJ;		
DR	WPI; 2002-527700/56.		
DR	P-RSDB; ABB81636.		
PT	Novel zycytoris polypeptides and polynucleotides useful for stimulating immune responses in animals for producing antibodies, and for treating autoimmune diseases, leukemia and asthma -		
PS	Claim 2; Page 160-163; 200pp; English,		
CC	The present invention describes an isolated human zcytor19 protein (I), and truncated zcytor19 proteins. (I) has immunosuppressive, cytostatic, antihemetic, antitarrhetic, neuroprotective, anti-inflammatory, antidiabetic, nephrotoprotic, dermatological, anti-HIV and haemostatic activities, and can be used in vaccines. (I) or an antibody binding (I) can be used for suppressing the immune system for reducing rejection of tissue or organ transplants and grafts and for treating T-cell specific leukemias or lymphomas and autoimmune diseases including rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel disease and Crohn's disease. The antibodies can also be used for treating immunologic renal diseases, glomerulonephritis, mesangioloproliferative disease, chronic lymphocytic leukaemia, secondary glomerulonephritis or vasculitis associated with lupus, polyarteritis, scleroderma, HIV-related diseases, amyloidosis and hemolytic uremic syndrome. (I) and the antibodies can also be used for renal or urological neoplasms and multiple myeloma, asthma, bronchitis, emphysema and other chronic airway diseases. Human zcytor19 is located to chromosome 1, more specifically to chromosome ip36.11. The present sequence encodes a human zcytor19 protein from the present invention.		
SQ	Sequence 1476 BP; 309 A; 439 C; 456 G; 272 T; 0 other;		
Query Match	84.7%; Score 1354.2; DB 24; Length 1476;		
Best Local Similarity	93.9%; Pred. No. 0;		
Matches 1467; Conservative 0; Mismatches 8; Indels 88; Gaps 2			
DG	1 ATGGCGGGGCCCGAGACGCCTGTGGGGCCCCCTGTCCTTGCGCTGTCGAGGCGCTTCAAGG 66		
DG	ATGGCGGGGCCCGAGACGCCTGTGGGGCCCCCTGTCCTTGCGCTGTCGAGGCGCTTCAAGG 60		
DG	AGGCGCCCGCTTGGGCGCCTCTCCCGAATTGAAGCTGCTCTCCAGAACTTCAAGGTTAC 126		
DG	AGGCGCCCGCTTGGGCGCCTCTCCCGAATTGAAGCTGCTCTCCAGAACTTCAAGGTTAC 120		
DG	CTGACATGGCTTCCAAGGGCTTGGCAAACCCCGAGATGTAACTATTATTGTGGCC -ATCA 185		
DG	CTGACATGGCTTCCAAGGGCTTGGCAAACCCCGAGATGTAACTATTATTGTGGCTATCA 180		
DG	AGCTCTTCCCACCCTTAACGCTGGCGCAAGTGAAGAAGTGTCGGGAACAAGAACCTG 245		

Db 181 AGCTCTCCACCCGTGAGCGGTGGCGCAAGTGAAGAGTGTGGGGGAAACCAAGAGACTG 240
 QY 246 CTATGTTCTATGATATGCTGTGAAGAAACAGAGACTTGTACACAGTTTGAAGGACGGCTG 305
 Db 241 CTATGTTCTATGATATGCTGTGAAGAAACAGAGACTTGTACACAGTTTGAAGGACGGCTG 300
 QY 306 CCGAGCGTTTCTCCAGAGTCCAGAGTCCCGCTGGGTGAGTCCGAAATCTTGATTAACCTT 365
 Db 301 CCGAGCGTTTCTCCAGAGTCCAGAGTCCCGCTGGGTGAGTCCGAAATCTTGATTAACCTT 360
 QY 366 TTTGAAGTGAAGCGCGGCCCACTGTCTGTGGTCTCAACCGAGCGAGAGATCTTGAGT 425
 Db 361 TTTGAAGTGAAGCGCGGCCCACTGTCTGTGGTCTCAACCGAGCGAGAGATCTTGAGT 420
 QY 426 GCCAATGCCAGTACACAGCTGCCCCCTGTGATGCCCACTTGATTTGAAGTATGAGTGT 485
 Db 421 GCCAATGCCAGTACACAGCTGCCCCCTGTGATGCCCACTTGATTTGAAGTATGAGTGT 480
 QY 486 GCATTCTGGAAGAGAGGGGGCGGAAACAAGACCTATTCCAGTCACTCCCAATGGCCAG 545
 Db 481 GCATTCTGGAAGAGAGGGGGCGGAAACAAGACCTATTCCAGTCACTCCCAATGGCCAG 540
 QY 546 CCAATCTCAGATCACTTCCAGCAAGCTGCCAGCAACAACATGCTCAGTGCAGAACCC 605
 Db 541 CCAATCTCAGATCACTTCCAGCAAGCTGCCAGCAACAACATGCTCAGTGCAGAACCC 600
 QY 606 ATCTACAGTTCAGTGTCCGAAATACAGCAAGTTCTCTAAGGCCACCTGCTTCTTGCTG 665
 Db 601 ATCTACAGTTCAGTGTCCGAAATACAGCAAGTTCTCTAAGGCCACCTGCTTCTTGCTG 660
 QY 666 GAGGTCCCAAGAGGAACTGGGCTTCTGTGTGCTGCCAATGCTTGTATATCTGTGTTA 725
 Db 661 GAGGTCCCAAGAGGAACTGGGCTTCTGTGTGCTGCCAATGCTTGTATATCTGTGTTA 720
 QY 726 GTAAATTGCGAGGGGGTGTGATCTGGAAGAACCTCATGGGAAACCTTGTTTCAGCGG 785
 Db 721 GTAAATTGCGAGGGGGTGTGATCTGGAAGAACCTCATGGGAAACCTTGTTTCAGCGG 780
 QY 786 GCAAGATGCAAGGGGGCTGGACCTTTCTGAGACACACACCTGTGGCAACCTTTCAG 845
 Db 781 GCAAGATGCAAGGGGGCTGGACCTTTCTGAGACACACACCTGTGGCAACCTTTCAG 840
 QY 846 CCCAGCAGACCAAGTCCGTGAATGACTTGTCTGTGCCCAAGAAAGAACTGACCA 905
 Db 801 -----GGAACGACACGA 813
 QY 906 GGGGTCAGGGCCGAGCCCTGAGTCAAGGGGCCCAAGCCCAACAGACAGATGGAAGAG 965
 Db 814 GGGGTCAGGGCCGAGCCCTGAGTCAAGGGGCCCAAGCCCAACAGACAGATGGAAGAG 873
 QY 966 GACCTTGCAGAGACGAAAGAGAGAGATGAGAGACACAGAAATGAGCTCAGCTTC 1025
 Db 874 GACCTTGCAGAGACGAAAGAGAGAGATGAGAGACACAGAAATGAGCTCAGCTTC 933
 QY 1026 CAGCCCTACATGTAACCACTTCTTCCGGGGGCAAGAGCCAGAGCTCCAGGGCACTCG 1085
 Db 934 CAGCCCTACATGTAACCACTTCTTCCGGGGGCAAGAGCCAGAGCTCCAGGGCACTCG 993
 QY 1086 GAGGCTGTGGGGTGTGACTCAGAGAGAGCCCAAGAGCTCTCTGTGCTCCAAACGAAAGCTTC 1145
 Db 994 GAGGCTGTGGGGTGTGACTCAGAGAGAGCCCAAGAGCTCTCTGTGCTCCAAACGAAAGCTTC 1053
 QY 1146 TCTGCTTGGGATCTTCTCAGACAGAGCTGGGCGAGCACTGTGGACCTCTCTGGGACAGG 1205
 Db 1054 TCTGCTTGGGATCTTCTCAGACAGAGCTGGGCGAGCACTGTGGACCTCTCTGGGACAGG 1113
 QY 1206 GCTGGGCTCTCTGGCTATTTGGCTGAGAAAGGGGCGCAAGGGCGGGTGGGAGATGGG 1265
 Db 1114 GCTGGGCTCTCTGGCTATTTGGCTGAGAAAGGGGCGCAAGGGCGGGTGGGAGATGGG 1173
 QY 1266 CACCAAGAAATCTCTCCACACCTGAAATTTCTTCAAGAGACTCGGGTTTCTTGAAGAGCTC 1325
 Db 1174 CACCAAGAAATCTCTCCACACCTGAAATTTCTTCAAGAGACTCGGGTTTCTTGAAGAGCTC 1233

QY 1326 CCAGAGATTAACCTTCTCTCTGGGCACTTGAGGACCTTACACACGAGCCGAAATCTG 1385
 Db 1234 CCAGAGATTAACCTTCTCTCTGGGCACTTGAGGACCTTACACACGAGCCGAAATCTG 1293
 QY 1386 GTCCCTGGGGAGACCCCACTTCTCTTCAAGACATGACCTTGTGGGAAAGAGCCCT 1445
 Db 1294 GTCCCTGGGGAGACCCCACTTCTCTTCAAGACATGACCTTGTGGGAAAGAGCCCT 1353
 QY 1446 GAGAGAGAAAGAGAGGCGAGGAAATCAGAAATTGAGGACAGCGATGCGGCGAGCTGGGG 1505
 Db 1354 GAGAGAGAAAGAGAGGCGAGGAAATCAGAAATTGAGGACAGCGATGCGGCGAGCTGGGG 1413
 QY 1506 GCTGAGAGACCCAGAGAGACCGAGGACAGGGGCGGACATTTGGGGCAATTACATGGCCAG 1565
 Db 1414 GCTGAGAGACCCAGAGAGACCGAGGACAGGGGCGGACATTTGGGGCAATTACATGGCCAG 1473
 QY 1566 TGA 1568
 Db 1474 TGA 1476
 RESULT 4
 AAD50485
 ID AAD50485 standard; cDNA, 1476 BP.
 XX
 AC AAD50485;
 XX
 DT 24-MAR-2003 (first entry)
 XX
 DE Human zcytor19 receptor variant cDNA.
 XX
 KW Human; leukemia; carcinoma; acquired immune deficiency syndrome; AIDS; melanoma; Kaposi's sarcoma; multiple myeloma; non-Hodgkin's lymphoma; hepatitis; infection; myocarditis; blood vessel formation; gene therapy; growth regulation; developmental process; immunotherapy; zcytor19; gene; receptor; variant; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 1..1476
 FT FT /tag= a
 FT FT /product= "Human zcytor19 receptor variant"
 FT sig_peptide 1..60
 FT FT /tag= b
 FT mat_peptide 61..1473
 FT FT /tag= c
 FT FT /product= "Mature human zcytor19 receptor variant"
 XX
 PN MO200286087-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 19-APR-2002; 2002M0-US12887.
 XX
 PR 20-APR-2001; 2001US-285408P.
 PR 20-APR-2001; 2001US-285408P.
 PR 25-APR-2001; 2001US-286482P.
 PR 29-JUN-2001; 2001US-0895834.
 PR 22-OCT-2001; 2001US-341050P.
 PR 22-OCT-2001; 2001US-341050P.
 XX
 PA (ZYMO) ZYMOGENETICS INC.
 XX
 PI Sheppard PO, Fox BA, Klucher KM, Taft DW, Kinsavogel WR,
 DR WPI; 2003-093122/08.
 DR P-PSDB; AAB32766.
 XX
 XX New zcyto20, zcyto21, zcyto22, zcyto24 and zcyto25 polypeptides and
 PT polynucleotides useful for treating leukemia, carcinoma, malignant
 PT melanoma, AIDS-related, Kaposi's sarcoma, myeloma, non-Hodgkin's

KM mesangiolipofliferative disease; chronic lymphocytic leukemia; bronchitis;
 KM secondary glomerulonephritis; scleroderma; amyloidosis; multiple myeloma;
 KM haemolytic uraemic syndrome; renal neoplasm; urological neoplasm;
 KM emphysema; chronic airway disease; chromosome 1; chromosome 1p36.11;
 KM gene; 88.
 OS Homo sapiens.
 XX WO200244209-A2.
 XX 06-JUN-2002.
 XX 28-NOV-2001; 2001NO-US44808.
 XX 28-NOV-2000; 2000US-253561P.
 XX 07-FEB-2001; 2001US-267211P.
 XX (ZYMO) ZYMOGENETICS INC.
 XX Presnell SR, Xu W, Novak JE, Whitmore TE, Grant FU,
 PI WPI; 2002-527700/56.
 DR Novel Zcytor19 polypeptides and polynucleotides useful for stimulating
 PT immune responses in animals for producing antibodies, and for treating
 PS autoimmune diseases, leukemia and asthma -
 XX Disclosure; Page 187-188; 200pp; English.
 XX The present invention describes an isolated human zcytor19 protein (1),
 CC and truncated zcytor19 proteins. (1) has immunosuppressive, cytostatic,
 CC antineoplastic, antiproliferative, neuroprotective, anti-inflammatory,
 CC antidiabetic, nephroprotective, dermatological, anti-HIV and haemostatic
 CC activities, and can be used in vaccines. (1) or an antibody binding (1)
 CC can be used for suppressing the immune system for reducing rejection of
 CC tissue or organ transplants and grafts and for treating T-cell specific
 CC leukemias or lymphomas and autoimmune diseases including rheumatoid
 CC arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel
 CC disease and Crohn's disease. The antibodies can also be used for treating
 CC immunologic renal diseases, glomerulonephritis, mesangiolipofliferative
 CC disease, chronic lymphocytic leukemia, secondary glomerulonephritis or
 CC vasculitis associated with lupus, polyarteritis, scleroderma, HIV-related
 CC diseases, amyloidosis and haemolytic uraemic syndrome. (1) and the
 CC antibodies can also be used for renal or urological neoplasms and
 CC multiple myelomas, asthma, bronchitis, emphysema and other chronic
 CC airway diseases. Human zcytor19 is located to chromosome 1, more
 CC specifically to chromosome 1p36.11. The present sequence represents a
 CC degenerate nucleotide sequence encoding a human zcytor19 protein from
 CC the present invention.
 CC
 SO Sequence 1560 BP; 221 A; 209 C; 286 G; 173 T; 671 other;

Query Match 68.0%; Score 1086.8; DB 24; Length 1560;
 Best Local Similarity 57.0%; Pred. No. 2.1e-271;
 Matches 888; Conservative 355; Mismatches 315; Indels 1; Gaps 1;

QY 7 ATGGGGGGGCGGAGCGTGGGGGCGGCGTCTCTGCTGCTGCAAGCGGCTCCAGG 66
 DB 1 ATGGCGGCGCGGAGCGTGGGGGCGGCGTCTCTGCTGCTGCAAGCGGCTCCAGG 60
 QY 67 AGGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 126
 DB 61 MGNCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 120
 QY 127 CTGACATGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 185
 DB 121 YTNACATGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 180
 QY 186 AGCTCTCCACCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 245
 DB 181 WSNWNCNACGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 240
 QY 246 CTATGTTCTATGATGCGCTGGAAGAAACAGAGCTGTACACAGTTCAAGGACCGCTG 305

DB 241 YTNWGSNVAATATGTGTTAAABARCAAGAYTTTAAVAAATTAARAGGAGGNTG 300
 QY 306 CGAAGCGTCTCCAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 365
 DB 301 MGNACGTTGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 360
 QY 366 TTTGAAGTGAAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 425
 DB 361 TTYGARGTGAAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 420
 QY 426 GCCAATGCCAGTACGCTGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 485
 DB 421 GGNAAVGCAGTATCAATGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 480
 QY 486 GCATTCGGAAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 545
 DB 481 GCATTCGGAAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 540
 QY 546 CCAGTCCAGATCACTCTCCAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 605
 DB 541 CCAGTCCAGATCACTCTCCAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 600
 QY 606 ATCTACAGTCACTCTCCAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 665
 DB 601 ATCTACAGTCACTCTCCAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 660
 QY 666 GAGGTCGGAAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 725
 DB 661 GAGGTCGGAAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 720
 QY 726 GATATTCGGAAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 785
 DB 721 GATATTCGGAAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 780
 QY 786 GCAAGATGCAAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 845
 DB 781 GCAAGATGCAAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 840
 QY 846 CCAGTCCAGATCACTCTCCAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 905
 DB 841 CCAGTCCAGATCACTCTCCAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 900
 QY 906 GGGGTCGGAAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 965
 DB 901 GGGGTCGGAAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 960
 QY 966 GACTTCGGAAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1025
 DB 961 GACTTCGGAAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1020
 QY 1026 CAGGCTCAATGCAAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1085
 DB 1021 CAGGCTCAATGCAAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1080
 QY 1086 GAGGCTCAATGCAAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1145
 DB 1081 GAGGCTCAATGCAAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1140
 QY 1146 TCTGCTGGAATCTTCAAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1205
 DB 1141 TCTGCTGGAATCTTCAAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1200
 QY 1206 GCTGGGCTCTGCTGGAATCTTCAAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1265
 DB 1201 GCTGGGCTCTGCTGGAATCTTCAAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1260
 QY 1266 CACCAAGATCTTCCAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1325
 DB 1261 CACCAAGATCTTCCAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1320
 QY 1326 CCAAGATTAATCTTCTCTGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1385

[illegible]

PH	Key	Location/Qualifiers
FT	CDS	123..1922
FT		/tag= A
FT		/product= "maltose binding protein (MBP) and human zcytoris fusion protein"
PN		MO20024420-A2.
XX		
PD		06-JUN-2002.
PP		28-NOV-2001; 2001MO-US44808.
XX		
PR		28-NOV-2000; 2000US-253561P.
XX		07-FEB-2001; 2001US-267211P.
PA		(ZYMO) ZYMOGENETICS INC.
XX		
P1		Presnell SR, Xu W, Novak JE, Whitmore TE, Grant FJ,
DR		WPI: 2002-527700/56.
XX		P-PDB: ABB81646.
PT		Novel Zcytoris polypeptides and polynucleotides useful for stimulating immune responses in animals for producing antibodies, and for treating autoimmune diseases, leukemia and asthma -
XX		
PS		Example 10; Page 189-193; 200Pp; English.
CC		The present invention describes an isolated human zcytoris protein (I),
CC		and truncated zcytoris proteins. (I) has immunosuppressive, cytoprotective,
CC		antirheumatic, antiarthritis, neuroprotective, antiinflammatory,
CC		antidiabetic, nephroretropic, dermatological, anti-HIV and haemostatic
CC		activities, and can be used in vaccines. (I) or an antibody binding (I)
CC		can be used for suppressing the immune system for reducing rejection of
CC		lensae or organ transplants and grafts and for treating T-cell specific
CC		leukemias or lymphomas and autoimmune diseases including rheumatoid
CC		arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel
CC		disease and Crohn's disease. The antibodies can also be used for treating
CC		immunologic renal diseases, glomerulonephritis, mesangiolipoferric or
CC		disease, chronic lymphocytic leukemia, secondary glomerulonephritis or
CC		vaccinitis associated with lupus, polyarteritis, scleroderma, HIV-related
CC		diseases, amyloidosis and hemolytic uremic syndrome. (I) and the
CC		antibodies can also be used for renal or urological neoplasms and
CC		multipple myelomas, ascites, bronchitis, emphysema and other chronic
CC		airway diseases. Human zcytoris is located to chromosome 1, more
CC		specifically to chromosome 1p35.11. The present sequence encodes a
CC		maltose binding protein (MBP) and human zcytoris fusion protein from
XX		the present invention.
SQ		Sequence 1922 BP; 503 A; 517 C; 503 G; 399 T; 0 other;
		Query Match 38.1%; Score 609.4; DB 24; Length 1922;
		Best Local Similarity 97.4%; Pred. No. 1.1e-147;
		Matches 600; Conservative 0; Mismatches 161; Indels 1; Gaps 1.
Oy	46	CTGTGCAAGCGCCTTCAGAGAGGCCCGCTGTGACCCCTTCCCAGAAATGTGACGTGCTC 105
Db	1266	CGCGTGATTCCGGTAGAATCCAGAGCCCCGTGTGGCCCCCTCCAGAAATGTGAAGCTGC 1325
Oy	106	TCCCAAGACTTCAGCTGTGACCTGTGACATGTGAGCTCCAGAGGCTTTGCAACCCCAAGATGTG 165
Db	1326	TCCCAAGACTTCAGCTGTGACCTGTGACATGTGAGCTCCAGAGGCTTTGCAACCCCAAGATGTG 1385
Oy	166	AACATAATTTGTGGCCATCATAGAGCTCTCCACCCCTTAAGACGTTGGCCGAATGTGAAGAAG 224
Db	1386	AACATAATTTGTGGCCATCATAGAGCTCTCCACCCCTTAAGACGTTGGCCGAATGTGAAGAAG 1445B
Oy	225	TGTGCGGGAACCAAGAGCTGTATATTTCTATATATATGTGCTTGAAGAAACAGACCTGTAC 284
Db	1446	TGTGCGGGAACCAAGAGCTGTATATTTCTATATATATGTGCTTGAAGAAACAGACCTGTAC 1505D
Oy	285	AACAAGTTCAAGGAGACGGTGGAGACGGTTTCTTCACAGCTCCAAGTCCCTCGGATGAG 344

Db 1506 AACAGTTCAGAGGACGCGGTGCGAGGTTTCTCCAGCTCCAAATGCCCTGGTGAG 1565
 QY 345 TCGGAATACCTGGATATACCTTTTGAAGTGAAGCGGGCCCACTGCTGCTGCTAC 404
 Db 1566 TCGGAATACCTGGATATACCTTTTGAAGTGAAGCGGGCCCACTGCTGCTGCTAC 1625
 QY 405 CAGACGAGAGATCTGAGTGCCTAATGCGATACAGCTGCCCCCTGCATGCCCA 464
 Db 1626 CAGACGAGAGATCTGAGTGCCTAATGCGATACAGCTGCCCCCTGCATGCCCA 1685
 QY 465 CTGGATCTGGAATGAGTGGGATCTGGAAGAGAGGGGGCGGAAACAGACCTATT 524
 Db 1686 CTGGATCTGGAATGAGTGGGATCTGGAAGAGAGGGGGCGGAAACAGACCTATT 1745
 QY 525 CCAAGTACTCCCAATGCGCAGCAAGTGCATCTTCAAGCAGCTGCGCAGCAAC 584
 Db 1746 CCAAGTACTCCCAATGCGCAGCAAGTGCATCTTCAAGCAGCTGCGCAGCAAC 1805
 QY 585 CACTGCTCAGTGCAGAACCATCTACAGTTCAGTTCGCCAAATACAGACGTTCT 644
 Db 1806 CACTGCTCAGTGCAGAACCATCTACAGTTCAGTTCGCCAAATACAGACGTTCT 1865
 QY 645 AAGCCCACTGCTTCTTCTGCTGAGGTCCTCAAGGCAATGCGCTTT 691
 Db 1866 AAGCCCACTGCTTCTTCTGCTGAGGTCCTCAAGGCAATGCGCTTT 1912

RESULT 8
 AB073080
 ID AB073080 standard; cDNA; 1422 BP.
 AC AB073080
 DT 25-SBP-2002 (first entry)
 XX Zcytor19 and Fc4 fusion protein encoding cDNA SEQ ID NO:22.
 XX
 KM Human; zcytor19; cytokine receptor; immunosuppressive; cytostatic;
 KM antitumoral; antirheumatic; neuroprotective; anti-inflammation;
 KM antidiabetic; nephrotropic; dermatological; anti-HIV; haemostatic;
 KM vaccine; immune system; T-cell specific leukemia; lymphoma; lupus;
 KM diabetes mellitus; inflammatory bowel disease; Crohn's disease; asthma;
 KM immunologic renal disease; glomerulonephritis; vasculitis; polyarteritis;
 KM mesangiolipofiferative disease; chronic lymphocytic leukemia; bronchitis;
 KM secondary glomerulonephritis; scleroderma; amyloidosis; multiple myeloma;
 KM hemolytic uraemic syndrome; renal neoplasm; urological neoplasm;
 KM emphysema; chronic airway disease; chromosome 1; chromosome 1p36.11;
 KM Gene; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 Key Location/Qualifiers
 FT 1..1422
 FT /*tag= a
 FT /product= "zcytor19-Fc4 fusion protein"
 XX
 PN NO200244209-A2.
 PD 06-JUN-2002.
 PD 28-NOV-2001; 2001MO-US44808.
 PD 28-NOV-2000; 2000US-253561P.
 PR 07-FEB-2001; 2001US-267211P.
 XX (ZYMO) ZYMOGENETICS INC.
 PA
 PI Presnell SR, Xu W, Novak JE, Whitmore TE, Grant FJ,
 XX MPI, 2002-527700/56.
 DR P-PSDB; ABB81645.

XX Novel Zcytor19 polypeptides and polynucleotides useful for stimulating
 PT immune responses in animals for producing antibodies, and for treating
 PT autoimmune diseases, leukemia and asthma.
 XX
 PS Example 4; Page 182-184; 2000P; English.
 XX
 CC The present invention describes an isolated human zcytor19 protein (I),
 CC and truncated zcytor19 proteins. (I) has immunosuppressive, cytostatic,
 CC antineoplastic, antirheumatic, neuroprotective, anti-inflammatory,
 CC antidiabetic, nephrotropic, dermatological, anti-HIV and haemostatic
 CC activities, and can be used in vaccines. (I) or an antibody binding (I)
 CC can be used for suppressing the immune system for reducing rejection of
 CC tissue or organ transplants and grafts and for treating T-cell specific
 CC leukemias or lymphomas and autoimmune diseases including rheumatoid
 CC arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel
 CC disease and Crohn's disease. The antibodies can also be used for treating
 CC immunologic renal diseases, glomerulonephritis, mesangiolipofiferative
 CC disease, chronic lymphocytic leukemia, secondary glomerulonephritis or
 CC vasculitis associated with lupus, polyarteritis, scleroderma, HIV-related
 CC diseases, amyloidosis and hemolytic uraemic syndrome. (I) and the
 CC antibodies can also be used for renal or urological neoplasms and
 CC multiple myelomas, asthma, bronchitis, emphysema and other chronic
 CC airway diseases. Human zcytor19 is located to chromosome 1, more
 CC specifically to chromosome 1p36.11. The present sequence encodes a human
 CC zcytor19-Fc4 fusion protein from the present invention.
 XX

Seq Sequence 1422 BP; 331 A; 451 C; 377 G; 263 T; 0 other;
 Query Match 38.0%; Score 607.4; DB 24; Length 1422;
 Best Local Similarity 99.7%; Pred. No. 3,4e-147;
 Matches 619; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 67. AGGCCCCGTCTGCGCCCTCCCAAGATGACCGTCTCTCCAGAACTTACGCGTAC 126
 Db 109 AGGCCCCGTCTGCGCCCTCCCAAGATGACCGTCTCTCCAGAACTTACGCGTAC 168
 QY 127 CTGACATGCTCTCCAGGCTTGGCAACCCCAAGATGACCTATTTTGTGGCC-ATAG 185
 Db 169 CTGACATGCTCTCCAGGCTTGGCAACCCCAAGATGACCTATTTTGTGGCCATAG 228
 QY 186 AGCTCTCCCAACCCGTGACGCTGCGGAGTGAAGTGTGCGGAAACCAAGAGCTG 245
 Db 229 AGCTCTCCCAACCCGTGACGCTGCGGAGTGAAGTGTGCGGAAACCAAGAGCTG 288
 QY 246 CTATGTTCTATGATGCTGCTGAAGAAACAGACCTGTACAAAGTTCAAGGACGCTG 305
 Db 289 CTATGTTCTATGATGCTGCTGAAGAAACAGACCTGTACAAAGTTCAAGGACGCTG 348
 QY 306 CGAGCGGTTTCTCCAGTCCAGTCCCTGCTGAGTCCGAATACCTGATTAACCTT 365
 Db 349 CGAGCGGTTTCTCCAGTCCAGTCCCTGCTGAGTCCGAATACCTGATTAACCTT 408
 QY 366 TTGGAAGTGAAGCGGCGCCCACTGCTGCTGCTACCCAGAGAGATCCTGAGT 425
 Db 409 TTGGAAGTGAAGCGGCGCCCACTGCTGCTGCTACCCAGAGAGATCCTGAGT 468
 QY 426 GCGAATGCGAAGTACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 485
 Db 469 GCGAATGCGAAGTACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 528
 QY 486 GCAATCTGAAGAGAGGGGGCGGAAACAGACCTATTTCAGTCACTCCCATGGCCAG 545
 Db 529 GCAATCTGAAGAGAGGGGGCGGAAACAGACCTATTTCAGTCACTCCCATGGCCAG 588
 QY 546 CCAATGCGAAGTACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 605
 Db 589 CCAATGCGAAGTACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 648
 QY 606 ATCTACAGTTCAGTTCGGAATACAGCAAGTTCCTAGCCCACTGCTTCTGCTG 665
 Db 649 ATCTACAGTTCAGTTCGGAATACAGCAAGTTCCTAGCCCACTGCTTCTGCTG 708


```

FT      1.60      /product= "Human zcytor19 truncated soluble receptor"
FT      1.60      /tag= b
FT      61.633    /tag= c
FT      /product= "Mature human zcytor19 truncated soluble
FT      receptor"
XX      WO200286087-A2.
XX      31-OCT-2002.
XX      19-APR-2002; 2002WO-US12887.
XX      20-APR-2001; 2001US-285408P.
XX      20-APR-2001; 2001US-285424P.
XX      25-APR-2001; 2001US-285482P.
XX      29-JUN-2001; 2001US-089583A.
XX      22-OCT-2001; 2001US-341050P.
XX      22-OCT-2001; 2001US-341105P.
XX      (ZYMO ) ZYMOGENETICS INC.
XX      Shepard PO, Fox BA, Klucher KM, Taft DM, Kindavogel WR;
XX      WPI, 2003-093122/08.
XX      P-PSDB; AAE32768.
XX      New zcyto20, zcyto21, zcyto22, zcyto24 and zcyto25 polypeptides and
XX      PT polynucleotides useful for treating leukemia, carcinoma, malignant
XX      PT melanoma, AIDS-related Kaposi's sarcoma, myeloma, non-Hodgkin's
XX      PT lymphoma, hepatitis and infections
XX      PS Example 30; Page 147-148; 160pp; English.
XX      The invention relates to zcyto20, zcyto21, zcyto22, zcyto24 and zcyto25
XX      CC polypeptides and polynucleotides. Sequences of the invention are useful
XX      CC for treating hairy cell leukemia, renal cell or basal cell carcinoma,
XX      CC malignant melanoma, AIDS-related Kaposi's sarcoma, multiple myeloma,
XX      CC non-Hodgkin's lymphoma, hepatitis B, C or D, infections (e.g. bacterial,
XX      CC fungal or protozoal) or myocarditis. The invention is useful for growth
XX      CC regulation in the liver, blood vessel formation and other developmental
XX      CC processes. The invention is also useful in immunotherapy and gene
XX      CC therapy. The present sequence is human zcytor19 truncated soluble
XX      CC receptor cDNA.
XX      Sequence 674 BP; 128 A; 223 C; 182 G; 141 T; 0 other;
XX      Query Match 31.1%; Score 498; DB 25; Length 674;
XX      Best Local Similarity 99.8%; Pred. No. 5.8e-119;
XX      Matches 509; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
QY      7 ATGGCGGGGGCGGAGGCGTGGGGGCGCCCTGCTCTGTCGTCGTCAGAGCGGCTCCAGGG 66
DB      1 ATGGCGGGGGCGGAGGCGTGGGGGCGCCCTGCTCTGTCGTCGTCAGAGCGGCTCCAGGG 60
QY      67 AGGCGCCGCTGTGGCCCTCCCGAGATGTGACGCTGCTCCCGAAGCTTCAAGGTGTAC 126
DB      61 AGGCGCCGCTGTGGCCCTCCCGAGATGTGACGCTGCTCCCGAAGCTTCAAGGTGTAC 120
QY      127 CTGACATGGCTCCAGAGGCTTGGCAACCCCGAGATGTGACCTATTGTGGCC-ATCAG 185
DB      121 CTGACATGGCTCCAGAGGCTTGGCAACCCCGAGATGTGACCTATTGTGGCC-ATCAG 180
QY      186 AGCTTCCCAACCCGTTGAGAGCGTGGCGGAGATGTGAGTGGCGGAAACCAAGAGACTG 245
DB      181 AGCTTCCCAACCCGTTGAGAGCGTGGCGGAGATGTGAGTGGCGGAAACCAAGAGACTG 240
QY      246 CTATGTTCTATGATGTGCTGTGAAGAAACAGAGACTGTGACCAAGATTCAAGGAGCGGTG 305
DB      241 CTATGTTCTATGATGTGCTGTGAAGAAACAGAGACTGTGACCAAGATTCAAGGAGCGGTG 300
QY      306 CGAGCGTTTCTCCCAAGCTCCAAAGTCCCGCGGTGGATCGGAATACCTGATTACCTT 365

```

```

DB      301 CGAGCGTTTCTCCCAAGCTCCAAAGTCCCGGTGGAGTCCGAATCCTGATTAACCTT 360
QY      366 TTGGAAGTGAAGCGCGGCCACCTGCTCTGTGTCTACACCAAGAGAGATCCTGACT 425
DB      361 TTGGAAGTGAAGCGCGGCCACCTGCTCTGTGTCTACACCAAGAGAGATCCTGACT 420
QY      426 GCGAATGCGACGTTACGAGCTGCGCCCTGTCATGCGCCCACTGATCTGAAGTATGAGTG 485
DB      421 GCGAATGCGACGTTACGAGCTGCGCCCTGTCATGCGCCCACTGATCTGAAGTATGAGTG 480
QY      486 GCATTCTGGAAGAGAGGGGCGCGGAAACAAG 515
DB      481 GCATTCTGGAAGAGAGGGGCGCGGAAACAAG 510
RESULT 11
ID      AAD35324 standard; DNA; 704 BP.
XX      AAD35324;
AC      25-JUL-2002 (first entry)
DE      Human (DNAX interferon like receptor subunit 4) DIRS4 DNA.
XX      Human; morphogenesis; DNAX interferon like receptor subunit 4; DIRS4;
XX      KM immune system; cytokine receptor; tumour necrosis factor; TNF; TNF;
XX      KM toll like receptor like molecule; TLR-L; transforming growth factor;
XX      KM TNF; 58856; claudin; schlafen; gene therapy; vaccine; immunological;
XX      KM medical disorder; gene; de.
XX      OS Homo sapiens.
XX      FH Key location/Qualifiers
FT      CDS 1..636
FT      /tag= a
FT      /product= "Human DIRS4 protein"
XX      PN WO200220569-A2.
XX      PD 14-MAR-2002.
XX      PF 07-SEP-2001; 2001WO-US28013.
XX      PR 08-SEP-2000; 2000US-231267P.
XX      PA (SCHE ) SCHERING CORP.
XX      PI Parham CL, Gorman DM, Kurata H, Arai N, Sana TR, Matison JD,
XX      PI Murphy BE, Savkoor C, Grein J, Smith KM, Mcclanahan TK,
XX      DR WPI; 2002-362239/39.
XX      P-PSDB; AAE22212.
XX      PT Recombinant polypeptide for immunizing a subject, comprises
XX      PT non-overlapping segments of amino acids identical to cytokine receptor
XX      PT sequences
XX      PS Claim 16; Page 95-96; 211pp; English.
XX      The present invention relates to compositions and methods for affecting
XX      CC mammalian physiology, including morphogenesis or immune system function.
XX      CC The invention particularly relates to recombinant polypeptides comprising
XX      CC 3 distinct non-overlapping segments of four amino acids identical to
XX      CC cytokine receptors, e.g., cytokine receptor like molecular structures
XX      CC such as segments of the sequences of DNAX interferon like receptor
XX      CC subunit 4 (DIRS4), tumour necrosis factor (TNF or TNF), toll like
XX      CC receptor like molecules (TLR-L1 through TLR-L5), transforming growth
XX      CC factor (TGF), 58856, claudin and schlafen. Sequences of the invention
XX      CC are used to modulate physiology or development of a cell. They are also
XX      CC used in gene therapy and as vaccines. Nucleic acid sequences are useful
XX      CC as probes for detecting a level of respective genes or transcripts in

```


Yy 426 GCACATGACAGTGCACGGTCGCCCGCCCTGTAGATGCCCCCACTGGATCTGTAAATGAAGTAGTG 485
Db 421 GGNAAVGCNACNTRAYCARTTNCNCNCNTGYATGCGCNCAVTNGAATTAAATTAAGAATN 480

Oy 486 GCATTCTTGGAAAGAGGGGGCCGAGAACACGACTTATTTCACTCATCTCCCATGAGCC 543
Db 481 GCNTTYTGGAARGARGGGNCNGNAAYAAAGTNGGNNMNSNTTYCCNGCNCNCMMGNY 538

RESULT 13
ID AAF64460 standard; CDNA; 374 BP.
XX AAF64460;
AC AAF64460;
DT 09-APR-2001 (first entry)
XX
XX Novel human polynucleotide, SEQ ID NO: 216.
DE
XX Human; cytosolic; gene therapy; colon cancer; prostate cancer;
KM breast cancer; lung cancer; cancer detection; ss.
KK Homo sapiens.
OS
XX WO200102568-A2.
XX
XX 11-JAN-2001.
PD
PP 30-JUN-2000; 2000WO-US18374.
XX
PR 02-JUL-1999; 99US-0142310.
PR 02-JUL-1999; 99US-0142311.
XX
XX (CHIR) CHIRON CORP.
FA (HYSE-) HYSEQ INC.
XX
PI Williams LT, Escobedo J, Imitz NA, Garcia PD, Klingner J, Kassar A;
PI Reinhard C, Randazzo F, Kennedy GC, Pot D, Lamson G, Drmanac R,
PI Cherkajkov R, Drmanac S, Dickson M, Labat I, Leshowitz D;
PI Kita D, Garcia V, Jones LW, Strache-Crain B;
DR WPI, 2001-091805/10.

XX Library of polynucleotides for diagnosing a cancerous state of a
XX mammalian cell and detecting cancer, particularly of the colon or
XX prostate, comprises 3351 human polynucleotide sequences -
XX claim 9; Page 575; 1046pp; English.

XX The present sequence is one of 3351 sequences in a library of human
XX polynucleotides. The library is used to detect differentially expressed
XX genes correlated with a cancerous state of a mammalian cell and can
XX detect colon, prostate, breast and lung cancer. The library can be used
XX to produce probes for detection of mRNA and to produce additional copies
XX of the polynucleotides. The probes can be used for chromosome mapping of
XX the polynucleotide and for detection of transcription levels. Ribozymes
XX or antisense oligonucleotides can be generated. The polynucleotides and
XX their gene products are used as genetic or biochemical markers (e.g. in
XX blood or tissues) that will detect the earliest changes along the
XX carcinogenesis pathway and/or monitor the efficacy of therapies and
XX preventive interventions. The polynucleotides, polypeptides and
XX antibodies against them can be used in pharmaceutical compositions to
XX treat the cancers and proliferative disorders such as neoplasia,
XX dysplasia and hyperplasia.
XX
XX Sequence 374 BP; 71 A; 117 C; 107 G; 79 T; 0 other;

Query Match 21.0%; Score 335.4; DB 22; Length 374;
Best Local Similarity 95.4%; Pred. No. 6.3e-77;
Matches 356; Conservative 0; Mismatches 16; Indels 1; Gaps 1

23 GCTGGAGGCCCTCTGCTCTGTGCTCTGTGACAGCCGCTTCCAGAGAGCCCGCTGTGCCC 82

Dd	2	GGAGAGAGGCCCTGTTCCTGTGCTCTGTGACGGCGCTCAGGGAAGGCCCGTCTGGCCC	61
Qy	83	CTCCCCAGAAATGTGACGCTGTCTCTCCCGAACTTCAGCGTGTACCTGACATAGGCTCCAG	144
Dd	62	CTCCCCAGAAATGTGACGCTGTCTCTCCCGAACTTCAGCGGAGTACCTGACATAGGCTCCAG	122
Qy	143	GGCTTGGCAACCCCCAGAGATGTGACCTATTTTGTGGCC-ATCAGAGCTCTCCACCGCTA	203
Dd	122	GGCTTGGCAACCCCCAGAGATGTGACCTATTTTGTGGCCATCAGAGCTCTCCACCGCTA	181
Qy	202	GACCGGTGGCGGAAGTGAAGAGTGTGGGGGACCAAGAGAGCTGTATTTGTATGATGT	263
Dd	182	GACCGGTGGCGGAAGTGAAGAGTGTGGGGGACCAAGAGAGCTGTATTTGTATGATGT	241
Qy	262	GCTGTGAAGAAACAGAGACTGTACCAACAGTTCAAGGAGCGGTGGGACGTTTCTCCCA	322
Dd	242	GCTGTGAAGAAACAGAGACTGTACCAACAGTTCAAGGAGCGGTGGGACGTTTCTCCCA	300
Qy	322	GCTCCAGTAGTCCCCCTGGGTGAGTCCGAATACCTGTGATTCCTTTTGAAGTGAAGCCGG	382
Dd	302	GCTCCAGTAGTCCCCCTGGGTGAGTCCGAATACCTGTGATTCCTTTTGAAGTGAAGCCGG	360
Qy	382	CCCCACCTGTCTCT 394	
Dd	362	CCCCACCTGTCTCT 374	
RESULT 14.			
ID	AAf65622/c		
ID	AAf65622 standard; cDNA; 392 BP.		
XX	AAf65622;		
AC			
XX	09-APR-2001 (first entry)		
DT			
XX			
DE	Novel human polynucleotide, SEQ ID NO: 1378.		
XX			
KW	Human; cytostatic; gene therapy; colon cancer; prostate cancer;		
KM	breast cancer; lung cancer; cancer detection; ss.		
XX			
OS	Homo sapiens.		
XX			
PN	WO200102568-A2.		
XX			
PD	11-JUN-2001.		
XX			
PF	30-JUN-2000; 2000MO-US18374.		
XX			
PR	02-JUL-1999; 99US-0142310.		
XX	02-JUL-1999; 99US-0142311.		
XX			
PA	(CHIR) CHIRON CORP.		
PA	(HYSE-) HYSEQ INC.		
XX			
PI	Williams LT, Escobedo J, Innis MA, Garcia PD, Klinger J, Kasam A,		
PI	Reinhard C, Randazzo P, Kennedy GC, For D, Lamson G, Drmanac R,		
PI	Cherkasov R, Drmanac S, Dickson M, Labat I, Leshkowitz D,		
PI	Kita D, Garcia V, Jones LM, Strache-Grain B;		
XX			
DR	WPI; 2001-091805/10.		
XX			
PT	Library of polynucleotides for diagnosing a cancerous state of a		
PT	mammalian cell and detecting cancer, particularly of the colon or		
PT	prostate, comprises 351 human polynucleotide sequences -		
XX			
PS	claim 9; Page 741; 1046pp; English.		
CC	The present sequence is one of 351 sequences in a library of human		
CC	polynucleotides. The library is used to detect differentially expressed		
CC	genes correlated with a cancerous state of a mammalian cell and can		
CC	detect colon, prostate, breast and lung cancer. The library can be used		
CC	to produce probes for detection of mRNA and to produce additional copies		

of the polynucleotides. The probes can be used for chromosome mapping of the polynucleotide and for detection of transcription levels. Ribozymes or antisense oligonucleotides can be generated. The polynucleotides and their gene products are used as genetic or biochemical markers (e.g. in blood or tissues) that will detect the earliest changes along the carcinogenesis pathway and/or monitor the efficacy of therapies and preventive interventions. The polynucleotides, polypeptides and antibodies against them can be used in pharmaceutical compositions to treat the cancers and proliferative disorders such as neoplasia, dysplasia and hyperplasia.

Sequence 392 BP; 76 A; 78 C; 132 G; 106 T; 0 other;

Query Match 10.3%; Score 165; DB 22; Length 392;
Best Local Similarity 97.1%; Pred. No. 9.1e-33;
Matches 168; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 510 AACAGACCTATTTCAGTCACTCCCGATGCGACGATCCAGATCACTCCAGCA 569
DB 207 AACAGACCTATTTCAGTCACTCCCGATGCGACGATCCAGATCACTCCAGCA 148
QY 570 GCTGCCAGGAAACACCACTGCTCACTGCGCAAAACATCTACAGTTCAGTCCGAA 629
DB 147 GCTGCCAGGAAACACCACTGCTCACTGCGCAAAACATCTACAGTTCAGTCCGAA 88
QY 630 TACAGCAAGTTCTCTAAGCCCACTGCTTCTTGCTGAGAGTCCAGAGCGAA 682
DB 87 TACAGCAAGTTCTCTAAGCCCACTGCTTCTTGCTGAGAGTCCAGAGCGAA 35

RESULT 15

AAF65522/c
ID AAF65522 standard; CDNA; 382 BP.

AAF65522;

09-APR-2001 (first entry)

Novel human polynucleotide, SEQ ID NO: 1278.

Human; cytosolic; gene therapy; colon cancer; prostate cancer; breast cancer; lung cancer; cancer detection; ss.

Homo sapiens.

MO200102568-A2.

11-JAN-2001.

30-JUN-2000; 2000MO-US18374.

02-JUL-1999; 99US-0142310.

02-JUL-1999; 99US-0142311.

(CHIR) CHIRON CORP.

(HXS-) HXSQ INC.

Williams LT, Escobedo J, Innis MA, Garcia PD, Klinger J, Kasam A, Reinhard C, Randazzo F, Kennedy GC, Pot D, Lamson G, Dymnac R, Cirenjakov R, Dymnac S, Dickson M, Labat I, Leshkowitz D, Kila D, Garcia V, Jones LM, Strache-Crain B;

WPI; 2001-091805/10.

Library of polynucleotides for diagnosing a cancerous state of a mammalian cell and detecting cancer, particularly of the colon or prostate, comprises 3351 human polynucleotide sequences -

Claim 9; Page 727; 1046pp; English.

The present sequence is one of 3351 sequences in a library of human polynucleotides. The library is used to detect differentially expressed genes correlated with a cancerous state of a mammalian cell and can

detect colon, prostate, breast and lung cancer. The library can be used to produce probes for detection of mRNA and to produce additional copies of the polynucleotides. The probes can be used for chromosome mapping of the polynucleotide and for detection of transcription levels. Ribozymes or antisense oligonucleotides can be generated. The polynucleotides and their gene products are used as genetic or biochemical markers (e.g. in blood or tissues) that will detect the earliest changes along the carcinogenesis pathway and/or monitor the efficacy of therapies and preventive interventions. The polynucleotides, polypeptides and antibodies against them can be used in pharmaceutical compositions to treat the cancers and proliferative disorders such as neoplasia, dysplasia and hyperplasia.

Sequence 382 BP; 77 A; 77 C; 130 G; 98 T; 0 other;

Query Match 10.2%; Score 163.4; DB 22; Length 382;
Best Local Similarity 96.5%; Pred. No. 2.3e-32;
Matches 167; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 510 AACAGACCTATTTCAGTCACTCCCGATGCGACGATCCAGATCACTCCAGCA 569
DB 207 AACAGACCTATTTCAGTCACTCCCGATGCGACGATCCAGATCACTCCAGCA 148
QY 570 GCTGCCAGGAAACACCACTGCTCACTGCGCAAAACATCTACAGTTCAGTCCGAA 629
DB 147 GCTGCCAGGAAACACCACTGCTCACTGCGCAAAACATCTACAGTTCAGTCCGAA 88
QY 630 TACAGCAAGTTCTCTAAGCCCACTGCTTCTTGCTGAGAGTCCAGAGCGAA 682
DB 87 TACAGCAAGTTCTCTAAGCCCACTGCTTCTTGCTGAGAGTCCAGAGCGAA 35

Search completed: September 17, 2003, 18:50:40
Job time : 315.324 secs